Based on the Aridis Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Aridis Pharmaceuticals Inc is not available over the next 12 months. Aridis Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aridis Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Aridis Pharmaceuticals Inc’s stock price was USD 0.00. Aridis Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -99.83% over the last year.
No recent analyst target price found for Aridis Pharmaceuticals Inc
No recent average analyst rating found for Aridis Pharmaceuticals Inc
Company Overview Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California. Read Less
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG...Read More
Frequently Asked Questions About Aridis Pharmaceuticals Inc (ARDS) Stock
Stock Target Advisor's fundamental analysis for Aridis Pharmaceuticals Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ARDS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ARDS's stock to indicate what its average analyst target is.
ARDS stock's Price/Earning ratio is 2.83.
Our analysis grades ARDS stock's Price / Earning ratio at D. This means that ARDS stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this ARDS may be fairly valued for its sector
The last closing price of ARDS's stock was USD 0.00.
The most recent market capitalization for ARDS is USD 4.46K.
Unfortunately we do not have enough analyst data on ARDS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aridis Pharmaceuticals Inc's stock.
As per our most recent records Aridis Pharmaceuticals Inc has 37 Employees.
Aridis Pharmaceuticals Inc's registered address is 983 University Avenue, Los Gatos, CA, United States, 95032.
You can get more information about it from Aridis Pharmaceuticals Inc's website at https://www.aridispharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Aridis Pharmaceuticals Inc (ARDS) Stock
Stock Target Advisor's fundamental analysis for Aridis Pharmaceuticals Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ARDS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ARDS's stock to indicate what its average analyst target is.
ARDS stock's Price/Earning ratio is 2.83.
Our analysis grades ARDS stock's Price / Earning ratio at D. This means that ARDS stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this ARDS may be fairly valued for its sector
The last closing price of ARDS's stock was USD 0.00.
The most recent market capitalization for ARDS is USD 4.46K.
Unfortunately we do not have enough analyst data on ARDS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aridis Pharmaceuticals Inc's stock.
As per our most recent records Aridis Pharmaceuticals Inc has 37 Employees.
Aridis Pharmaceuticals Inc's registered address is 983 University Avenue, Los Gatos, CA, United States, 95032.
You can get more information about it from Aridis Pharmaceuticals Inc's website at https://www.aridispharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARDS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
